<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116380</article-id><article-id pub-id-type="publisher-id">ACM-43083</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_59601367.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  FOXP1在卵巢癌中的作用及其机制
  The Role and Mechanism of FOXP1 in Ovarian Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>阳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>转</surname><given-names>黎</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>云秀</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胥</surname><given-names>琴</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>云南省第一人民医院生殖医学科，云南 昆明</addr-line></aff><aff id="aff2"><addr-line>昆明理工大学附属医院/云南省第一人民医院，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2633</fpage><lpage>2638</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  卵巢癌缺少早期诊断方法，而晚期患者通过肿瘤细胞减灭术和基础化疗等传统治疗方案后易复发，因此从卵巢癌发生发展的分子机制探索新的分子标志物和治疗靶点意义重大。Forkhead Box P1 (FOXP1)作为转录因子密切参与卵巢癌的发生发展进程，近些年的研究表明，高表达的FOXP1通过促进上皮–间充质转化、调节肿瘤干细胞特性、调控多种分子信号转导通路等机制影响卵巢癌细胞增殖、转移、侵袭和化疗抗性。本文通过简要论述转录因子FOXP1在卵巢癌中的作用及其机制研究的最新进展，旨在为卵巢癌早期诊断和临床治疗寻找新的分子靶标。
   There is a lack of early diagnosis of ovarian cancer, and advanced patients are prone to relapse after traditional treatment such as cytoreductive surgery and basic chemotherapy. Therefore, it is of great significance to explore new molecular markers and therapeutic targets from the molecular mechanism of ovarian cancer development. As a transcription factor, Forkhead Box P1 (FOXP1) is closely involved in the occurrence and development of ovarian cancer. Recent studies have shown that high expression of FOXP1 affects the proliferation, metastasis, invasion and chemotherapy resistance of ovarian cancer cells by promoting epithelial mesenchymal transition, regulating the characteristics of tumor stem cells, and regulating a variety of molecular signal transduction pathways. In this paper, we briefly discuss the role of FOXP1 in ovarian cancer and the latest progress of its mechanism, aiming to find a new molecular target for early diagnosis and clinical treatment of ovarian cancer.
 
</p></abstract><kwd-group><kwd>Forkhead Box P1，卵巢癌，治疗靶点, Forkhead Box P1</kwd><kwd> Ovarian Cancer</kwd><kwd> Therapeutic Targets</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>卵巢癌缺少早期诊断方法，而晚期患者通过肿瘤细胞减灭术和基础化疗等传统治疗方案后易复发，因此从卵巢癌发生发展的分子机制探索新的分子标志物和治疗靶点意义重大。Forkhead Box P1 (FOXP1)作为转录因子密切参与卵巢癌的发生发展进程，近些年的研究表明，高表达的FOXP1通过促进上皮–间充质转化、调节肿瘤干细胞特性、调控多种分子信号转导通路等机制影响卵巢癌细胞增殖、转移、侵袭和化疗抗性。本文通过简要论述转录因子FOXP1在卵巢癌中的作用及其机制研究的最新进展，旨在为卵巢癌早期诊断和临床治疗寻找新的分子靶标。</p></sec><sec id="s2"><title>关键词</title><p>Forkhead Box P1，卵巢癌，治疗靶点</p></sec><sec id="s3"><title>The Role and Mechanism of FOXP1 in Ovarian Cancer</title><p>Yang Chen<sup>1</sup>, Li Zhuan<sup>2</sup>, Yunxiu Li<sup>2</sup>, Qin Xu<sup>2*</sup></p><p><sup>1</sup>The Affiliated Hospital of Kunming University of Science and Technology/Yunnan First People’s Hospital, Kunming Yunnan</p><p><sup>2</sup>Department of Reproductive Medicine, Yunnan First People’s Hospital, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/22-1572256x4_hanspub.png" /></p><p>Received: May 10<sup>th</sup>, 2021; accepted: May 29<sup>th</sup>, 2021; published: Jun. 11<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/22-1572256x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>There is a lack of early diagnosis of ovarian cancer, and advanced patients are prone to relapse after traditional treatment such as cytoreductive surgery and basic chemotherapy. Therefore, it is of great significance to explore new molecular markers and therapeutic targets from the molecular mechanism of ovarian cancer development. As a transcription factor, Forkhead Box P1 (FOXP1) is closely involved in the occurrence and development of ovarian cancer. Recent studies have shown that high expression of FOXP1 affects the proliferation, metastasis, invasion and chemotherapy resistance of ovarian cancer cells by promoting epithelial mesenchymal transition, regulating the characteristics of tumor stem cells, and regulating a variety of molecular signal transduction pathways. In this paper, we briefly discuss the role of FOXP1 in ovarian cancer and the latest progress of its mechanism, aiming to find a new molecular target for early diagnosis and clinical treatment of ovarian cancer.</p><p>Keywords:Forkhead Box P1, Ovarian Cancer, Therapeutic Targets</p><disp-formula id="hanspub.43083-formula21"><graphic xlink:href="//html.hanspub.org/file/22-1572256x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/22-1572256x8_hanspub.png" /> <img src="//html.hanspub.org/file/22-1572256x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>卵巢癌是女性生殖系统最常见的三大恶性肿瘤之一，致死率居妇科恶性肿瘤首位，对女性生命与健康造成严重威胁 [<xref ref-type="bibr" rid="hanspub.43083-ref1">1</xref>]。近年来，通过随着肿瘤发生发展机制的不断研究，靶向特异性因子的恶性肿瘤免疫疗法吸引了众多学者的关注，但其仍处于初期研究阶段。因此，寻找通过特异因子治疗卵巢癌的方式至关重要 [<xref ref-type="bibr" rid="hanspub.43083-ref2">2</xref>]。</p><p>FOXP1是叉头框转录因子家族的成员，具有多种生理功能。近年来研究发现，FOXP1在卵巢癌的发生发展中具有促进作用，并与卵巢肿瘤的恶性生物学行为和化疗耐药密切相关 [<xref ref-type="bibr" rid="hanspub.43083-ref3">3</xref>]。本文期望通过重点阐述FOXP1促进卵巢癌细胞上皮–间充质转化、调节肿瘤干细胞特性等方面的具体作用机制，结合国内外的最新研究作一综述，为探索卵巢癌早期诊断和靶向治疗提供理论依据。</p></sec><sec id="s6"><title>2. FOXP1的分子结构与生理功能</title><p>FOXP1的编码基因位于3号染色体第1区第4带第1亚带，在结构上，由DNA结合域和蛋白质-蛋白质结合域两种结构域组成 [<xref ref-type="bibr" rid="hanspub.43083-ref4">4</xref>]。转录因子FOXP1的早期研究报道多是关于细胞正常发育、言语功能形成、调节运动神经元等生理成长方面。近年来，在肿瘤微环境中，研究者们普遍认为FOXP1可能是潜在的癌基因或是肿瘤抑制因子，而具体的功能和作用则取决于不同的细胞背景 [<xref ref-type="bibr" rid="hanspub.43083-ref5">5</xref>]。已发现FOXP1在B细胞淋巴瘤和肝细胞癌中高表达，并造成了较差恶性肿瘤结果。另一方面，在前列腺癌、子宫内膜癌等生殖肿瘤疾病中的较差结果与FOXP1表达丧失相关。这些相同结局下FOXP1的异常表达，说明转录因子FOXP1可能在不同肿瘤疾病的进程中发挥着重要作用 [<xref ref-type="bibr" rid="hanspub.43083-ref6">6</xref>]。</p></sec><sec id="s7"><title>3. FOXP1对卵巢癌发生发展的影响</title><p>转录因子FOXP1作为近年来发现的新型肿瘤标志物，可与DNA特异性结合，促进细胞周期GI期阻滞，导致细胞凋亡，促进肿瘤增殖。现有研究证据表明，FOXP1表达上调与卵巢癌临床分期密切相关，其通过提高肿瘤源性，促进卵巢癌的发生发展和化疗抗性 [<xref ref-type="bibr" rid="hanspub.43083-ref7">7</xref>]。</p><sec id="s7_1"><title>3.1. FOXP1促进卵巢癌细胞增殖、转移和侵袭</title><p>研究发现，FOXP1高表达的卵巢癌患者癌细胞活跃，更易发生侵染转移，肿瘤恶性程度较高。不仅如此，通过生物信息学分析FOXP1对卵巢癌患者生存率的影响，平均生存期降低的卵巢癌患者们，转录因子FOXP1的表达明显上升。为了解FOXP1与卵巢癌细胞间的相互影响。2015年Eun [<xref ref-type="bibr" rid="hanspub.43083-ref3">3</xref>] 等研究者通过慢病毒感染细胞进行FOXP1敲低和过表达实验，发现高表达FOXP1的卵巢癌细胞在形成肿瘤干细胞球状体时，相比较低表达的细胞，得到了尺寸更大、数量更多的球状体；同时发现球状体中所含细胞数与FOXP1的表达成正相关。当通过Transwell测定法测定细胞迁移、侵袭能力时，FOXP1过表达显著促进了细胞发生迁移和侵袭等行为。另外Hu等检测152例卵巢癌患者组织样本中FOXP1核酸和蛋白的表达，对比癌旁正常组织，发现FOXP1在卵巢癌组织中表达明显增加。</p><p>以上众多研究结果表明FOXP1在卵巢癌中高表达，促进了卵巢癌细胞增殖、转移和侵袭的生物学行为。而分子靶向治疗结合传统治疗方式已逐渐成为当今肿瘤疾病治疗的新手段。因此，FOXP1将有希望成为卵巢癌治疗的分子标志物。</p></sec><sec id="s7_2"><title>3.2. FOXP1参与卵巢癌细胞化疗抗性</title><p>卵巢癌传统治疗方式是肿瘤细胞减灭术后辅以药物进行化疗，大多数患者经过传统治疗后，病情得以缓解，但是随着药物化疗的逐渐治疗，几乎无一例外产生了化疗药物抗性，而化疗抗性的产生是肿瘤复发、癌症死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.43083-ref8">8</xref>]。因此，如何解决卵巢癌治疗过程中产生的化疗抗性，成为提高卵巢癌疗效的关键问题。研究发现，在药物敏感型和抗药型的卵巢癌组织样中分析比较，抗药型组织样中FOXP1蛋白表达显著上调，同时，过表达FOXP1增强了卵巢癌细胞对化疗药物的抗性，相反，抑制FOXP1的表达，减少了卵巢癌细胞对化疗药物的抗性 [<xref ref-type="bibr" rid="hanspub.43083-ref9">9</xref>]。相似的研究证实抑制自噬基因ATG14的表达，可以增强顺铂耐药卵巢癌细胞顺铂药物的敏感性；研究者们通过顺铂耐药细胞和顺铂敏感细胞比较分析，发现FOXP1和自噬相关蛋白ATG14和MDR-1在蛋白表达水平上耐药细胞明显高于敏感细胞，而细胞核中FOXP1表达量明显增加，表明更多的FOXP1从细胞质传送到细胞核，以充当转录因子，实现LC3II/LC3-I蛋白表达比例和BECLIN1蛋白表达增加，从而诱导耐药细胞发生自噬行为，增强卵巢癌细胞对化疗药物的抗性。随着研究的不断深入，在人卵巢癌细胞中，基因芯片测定显示FOXP1与ATG14的启动子结合，在顺铂耐药细胞株中两者均普遍高表达，且存在显著相关性。FOXP1过表达增强了卵巢癌细胞对化疗药物的耐药能力，同时促进卵巢癌细胞中ATG14 mRNA和蛋白水平的表达。因此，不难发现FOXP1通过调节自噬因子ATG14、MDR-1等实现卵巢癌细胞产生化疗抗性。</p><p>以上众多研究结果表明，FOXP1在卵巢癌的化疗抵抗中起重要作用，可作为预测肿瘤耐药的关键分子标志物，也可能作为卵巢癌中克服化疗抗性的新靶标。</p></sec></sec><sec id="s8"><title>4. FOXP1在卵巢癌中的机制研究</title><p>转录因子FOXP1通过促进卵巢癌细胞发生EMT、调节肿瘤干细胞特性和调控信号转导通路等作用机制，实现在卵巢癌发生发展、转移和化疗抗性中重要的促进作用 [<xref ref-type="bibr" rid="hanspub.43083-ref10">10</xref>]。</p><sec id="s8_1"><title>4.1. FOXP1促进卵巢癌细胞发生EMT</title><p>上皮间充质转化(EMT)存在于肿瘤发生发展过程中，肿瘤细胞通过上皮间充质转化获得干细胞特性，在机体内进行转移，造成肿瘤扩散和复发 [<xref ref-type="bibr" rid="hanspub.43083-ref11">11</xref>]。转录因子FOXP1通过调节卵巢癌细胞发生EMT促进肿瘤的发生发展和化疗抗性，上调FOXP1在卵巢癌细胞中的表达，显著增加了N-钙粘蛋白(N-CADHERIN)、波形蛋白(VIMENTIN)等EMT相关基因的表达，通过减少肿瘤细胞之间的黏附特性，将不移动的上皮细胞转化为可移动的侵袭性间质细胞，导致细胞无限增殖，进而发生浸润和转移。综上所述，转录因子FOXP1在卵巢癌细胞中通过提高间质蛋白表达水平，使细胞获得间质特征，促进肿瘤细胞上皮间充质转化，诱导细胞发生侵袭、转移和化疗耐药。因此，未来期望通过FOXP1对卵巢癌转移、耐药进行评估，开发通过抑制卵巢癌EMT实现抗肿瘤转移、耐药的有效治疗方案。</p></sec><sec id="s8_2"><title>4.2. FOXP1调节肿瘤干细胞特性</title><p>据研究报道称，在恶性肿瘤的进程中，具有干细胞样特征的一小类细胞被称为肿瘤干细胞，其表现出较强的自我更新能力、高致瘤性和化疗抗性等，故被大家广泛认定为肿瘤转移和肿瘤复发的主要原因 [<xref ref-type="bibr" rid="hanspub.43083-ref12">12</xref>]。因此，关于卵巢癌中肿瘤干细胞特性的机制研究对于卵巢癌患者无复发性治疗的发展至关重要。随着对肿瘤干细胞研究的不断深入，确定卵巢癌中的转录因子FOXP1直接参与调节肿瘤干细胞的干性相关基因表达。通过对特征基因ABCG2、OCT4、NANOG、SOX2启动子进行报告分析，FOXP1的过表达显著增强了ABCG2、OCT4、NANOG、SOX2的转录活性 [<xref ref-type="bibr" rid="hanspub.43083-ref13">13</xref>]。当在每个报告构建体中搜索FOXP1的结合位点时，ABCG2、OCT4和SOX2的启动子显示出假定的FOXP1结合位点，而NONOG启动子没有，表明FOXP1参与上调卵巢癌肿瘤干细胞的特征基因表达。同时，通过体内实验研究发现，分别裸鼠注射FOXP1敲低、过表达卵巢癌细胞进行裸鼠成瘤实验。FOXP1敲低组产生的肿瘤重量，明显小于过表达组的肿瘤重量，此类现象表明FOXP1与卵巢癌肿瘤干细胞特征表现的直接相关性，推断FOXP1通过促进肿瘤干细胞特性发展相关基因的表达，在调节肿瘤干细胞特性方面发挥关键作用。总的来说，目前研究表明FOXP1通过促进卵巢癌细胞产生干细胞特性而作为癌基因发挥作用，未来有望通过FOXP1入手解决肿瘤干细胞难题，探索治疗卵巢癌的有效靶点。</p></sec><sec id="s8_3"><title>4.3. FOXP1调控分子信号转导通路</title><p>ATP结合盒(ABC)转运蛋白作为一类膜蛋白，具有逆浓度梯度将抗癌药物转运出细胞外的能力，使肿瘤细胞获得化疗抗性 [<xref ref-type="bibr" rid="hanspub.43083-ref14">14</xref>]。通过细胞实验研究发现，在卵巢癌细胞中，敲低FOXP1的表达，增加细胞对化疗药物敏感性的同时，降低了药物转运蛋白ABCB1、ABCG2、ABCC6等核酸水平的表达，而过表达FOXP1增加细胞化疗抗性同时，促进了ABCB1、ABCG2、ABCC6等核酸水平的表达。以上研究结果表明，卵巢癌细胞中FOXP1的表达与药物转运蛋白的表达和化疗药物耐药性呈正相关，促进了卵巢癌化疗抗性的产生。</p><p>雌激素在人类卵巢癌的进展中起着至关重要的作用，而雌激素是通过雌激素受体(ER)发挥作用 [<xref ref-type="bibr" rid="hanspub.43083-ref15">15</xref>]；受体可分两种不同的ER亚型：ERa和ERb，两者之间存在拮抗作用 [<xref ref-type="bibr" rid="hanspub.43083-ref16">16</xref>]。研究发现，在卵巢癌中雌激素可以诱导FOXP1基因的表达。通过免疫共沉淀和荧光双染色实验，了解到卵巢癌中FOXP1，ERa和ERb的共定位存在于细胞质中，而在卵巢癌组织样本中FOXP1蛋白表达水平在细胞质中明显增加，ERb在卵巢肿瘤中的表达模式与FOXP1蛋白相似，推测出FOXP1蛋白表达与核ERb表达成正相关，表明它们之间的相互作用可能促进卵巢癌的发展，为FOXP1和ER之间的关系提供了初步研究证据。然而，两种雌激素受体在卵巢癌中的作用关系尚有争议 [<xref ref-type="bibr" rid="hanspub.43083-ref17">17</xref>]，因此需要进一步研究才能确定雌激素与FOXP1两者在卵巢癌中作用机制的关联性。</p><p>MicroRNAs (miRNAs)是一类短链小分子非编码核糖核酸，具有靶向调控基因表达的功能 [<xref ref-type="bibr" rid="hanspub.43083-ref18">18</xref>]。研究表明，MicroRNAs通过调控肿瘤因子的表达，参与癌症的发生发展和化疗抗性的产生 [<xref ref-type="bibr" rid="hanspub.43083-ref19">19</xref>]。据研究报道，几种MicroRNAs的异常表达，通过与转录因子FOXP1组成信号调节通路参与调节卵巢癌的发生发展和化疗耐药的产生。譬如，MicroRNA‑152通过靶向抑制FOXP1的表达参与抑制卵巢癌细胞的增殖和迁移 [<xref ref-type="bibr" rid="hanspub.43083-ref20">20</xref>]，miR-29c-3p靶向下调FOXP1的蛋白表达从而抑制卵巢癌细胞发生自噬和顺铂化疗敏感性，miR-374b-5p在卵巢癌中抑制细胞增殖、迁移、上皮间充质转化和顺铂耐药；然而FOXP1通过抑制miR-374b-5p转录活性降低miR-374b-5p的表达。以上研究结果说明，MicroRNAs与转录因子FOXP1在卵巢癌中的研究至关重要，有希望制定以分子靶标为治疗手段的卵巢癌治疗新策略。</p></sec></sec><sec id="s9"><title>5. 结语</title><p>迄今为止，随着研究的不断深入，分子靶向治疗因其高效率、低危害等优势成为恶性肿瘤治疗的新趋势 [<xref ref-type="bibr" rid="hanspub.43083-ref21">21</xref>]。而转录因子FOXP1作为癌基因，通过促进上皮间充质转化、调节肿瘤干细胞特性、调控多种分子信号转导通路等机制，在卵巢癌的发生发展和化疗抗性中发挥重要作用。因此本文通过总结分析FOXP1在卵巢癌中作用及其机制的最新研究进展，为FOXP1作为卵巢癌诊断、治疗的新型标志物提供参考依据，根据这些机制的研究，将为卵巢癌的靶向治疗提供新的新思路和方向 [<xref ref-type="bibr" rid="hanspub.43083-ref22">22</xref>]。</p></sec><sec id="s10"><title>基金项目</title><p>国家自然科学基金项目(编号：81760470、81460234)；云南省临床医学中心开放项目(编号：2020LCZXKF-SZ01、2020LCZXKF-SZ011)云南省卫生和计划生育委员会医学学科带头人、医学后备人才培养项目(编号：D-2019018、D-2017022、H2017025)。</p></sec><sec id="s11"><title>文章引用</title><p>陈 阳,转 黎,李云秀,胥 琴. FOXP1在卵巢癌中的作用及其机制The Role and Mechanism of FOXP1 in Ovarian Cancer[J]. 临床医学进展, 2021, 11(06): 2633-2638. https://doi.org/10.12677/ACM.2021.116380</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43083-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Webb, P.M. and Jordan, S.J. (2017) Epidemiology of Epithelial Ovarian Cancer. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology, 41, 3-14. &lt;br&gt;https://doi.org/10.1016/j.bpobgyn.2016.08.006</mixed-citation></ref><ref id="hanspub.43083-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Narod, S. (2016) Can Advanced-Stage Ovarian Cancer Be Cured? Nature Reviews Clinical Oncology, 13, 255-261. 
&lt;br&gt;https://doi.org/10.1038/nrclinonc.2015.224</mixed-citation></ref><ref id="hanspub.43083-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Choi, E.J., Seo, E.J., Kim, D.K., Lee, S.I., Kwon, Y.W., Jang, I.H., et al. (2016) FOXP1 Functions as an Oncogene in Promoting Cancer Stem Cell-Like Characteristics in Ovarian Cancer Cells. Oncotarget, 7, 3506-3519.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.6510</mixed-citation></ref><ref id="hanspub.43083-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Katoh, M., Igarashi, M., Fukuda, H., Nakagama, H. and Katoh, M. (2013) Cancer Genetics and Genomics of Human FOX Family Genes. Cancer Letters, 328, 198-206. &lt;br&gt;https://doi.org/10.1016/j.canlet.2012.09.017</mixed-citation></ref><ref id="hanspub.43083-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Koon, H.B., Ippolito, G.C., Banham, A.H. and Tucker, P.W. (2007) FOXP1: A Potential Therapeutic Target in Cancer. Expert Opinion on Therapeutic Targets, 11, 955-965. &lt;br&gt;https://doi.org/10.1517/14728222.11.7.955</mixed-citation></ref><ref id="hanspub.43083-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kim, J.H., Hwang, J., Jung, J.H., Lee, H.-J., Lee, D.Y. and Kim, S.-H. (2019) Molecular Networks of FOXP Family: Dual Biologic Functions, Interplay with Other Molecules and Clinical Implications in Cancer Progression. Molecular Cancer, 18, Article No. 180. &lt;br&gt;https://doi.org/10.1186/s12943-019-1110-3</mixed-citation></ref><ref id="hanspub.43083-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Z., Zhu, L., Gao, J., Cai, M., Tan, M., Liu, J., et al. (2015) Expression of FOXP1 in Epithelial Ovarian Cancer (EOC) and Its Correlation with Chemotherapy Resistance and Prognosis. Tumor Biology, 36, 7269-7275. 
&lt;br&gt;https://doi.org/10.1007/s13277-015-3383-5</mixed-citation></ref><ref id="hanspub.43083-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hu, Z., Cai, M., Zhang, Y., Tao, L. and Guo, R. (2020) miR-29c-3p Inhibits Autophagy and Cisplatin Resistance in Ovarian Cancer by Regulating FOXP1/ATG14 Pathway. Cell Cycle, 19, 193-206. 
&lt;br&gt;https://doi.org/10.1080/15384101.2019.1704537</mixed-citation></ref><ref id="hanspub.43083-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ricci, F., Fratelli, M., Guffanti, F., Porcu, L., Spriano, F., Dell’Anna, T., et al. (2017) Patient-Derived Ovarian Cancer Xenografts Re-Growing after a Cisplatinum Treatment Are Less Responsive to a Second Drug Rechallenge: A New Experimental Setting to Study Response to Therapy. Oncotarget, 8, 7741-7451.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.7465</mixed-citation></ref><ref id="hanspub.43083-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nameki, R., Chang, H., Reddy, J., Corona, R.I. and Lawrenson, K. (2021) Transcription Factors in Epithelial Ovarian Cancer: Histotype-Specific Drivers and Novel Therapeutic Targets. Pharmacology &amp; Therapeutics, 220, Article ID: 107722. &lt;br&gt;https://doi.org/10.1016/j.pharmthera.2020.107722</mixed-citation></ref><ref id="hanspub.43083-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Li, H., Liang, J., Qin, F. and Zhai, Y. (2018) MiR-374b-5p-FOXP1 Feedback Loop Regulates Cell Migration, Epithelial-Mesenchymal Transition and Chemosensitivity in Ovarian Cancer. Biochemical and Biophysical Research Communications, 505, 554-560. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2018.09.161</mixed-citation></ref><ref id="hanspub.43083-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Liao, J., Qian, F., Tchabo, N., Mhawech-Fauceglia, P., Beck, A., Qian, Z., et al. (2014) Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism. PLoS ONE, 9, e84941. &lt;br&gt;https://doi.org/10.1371/journal.pone.0084941</mixed-citation></ref><ref id="hanspub.43083-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, L., Hu, Z., Liu, J. Gao, J. and Lin, B. (2015) Gene Expression Profile Analysis Identifies Metastasis and Chemoresistance-Associated Genes in Epithelial Ovarian Carcinoma Cells. Medical Oncology, 32, Article No. 426.  
&lt;br&gt;https://doi.org/10.1007/s12032-014-0426-5</mixed-citation></ref><ref id="hanspub.43083-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Roy, L. and Cowden Dahl, K.D. (2018) Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? Cancers (Basel), 10, Article No. 241. &lt;br&gt;https://doi.org/10.20944/preprints201806.0262.v1</mixed-citation></ref><ref id="hanspub.43083-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Giatromanolaki, A., Koukourakis, M.I., Sivridis, E., Gatter, K.C., Harris, A.L. and Banham, A.H. (2006) Loss of Expression and Nuclear/Cytoplasmic Localization of the FOXP1 Forkhead Transcription Factor Are Common Events in Early Endometrial Cancer: Relationship with Estrogen Receptors and HIF-1alpha Expression. Modern Pathology, 19, 9-16. &lt;br&gt;https://doi.org/10.1038/modpathol.3800494</mixed-citation></ref><ref id="hanspub.43083-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Bates, G.J., Fox, S.B., Han, C., Launchbury, R., Leek, R.D., Harris, A.L., et al. (2008) Expression of the Forkhead Transcription Factor FOXP1 Is Associated with That of Estrogen Receptor-Beta in Primary Invasive Breast Carcinomas. Breast Cancer Research and Treatment, 111, 453-459. &lt;br&gt;https://doi.org/10.1007/s10549-007-9812-4</mixed-citation></ref><ref id="hanspub.43083-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rayoo, M., Yan M., Takano, E.A., Bates, G.J., Brown, P.J., Banham, A.H., et al. (2009) Expression of the Forkhead Box Transcription Factor FOXP1 Is Associated with Oestrogen Receptor Alpha, Oestrogen Receptor Beta and Improved Survival in Familial Breast Cancers. Journal of Clinical Pathology, 62, 896-902.  
&lt;br&gt;https://doi.org/10.1136/jcp.2009.065169</mixed-citation></ref><ref id="hanspub.43083-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Sethi, S., Sethi, S. and Bluth, M.H. (2018) Clinical Implication of MicroRNAs in Molecular Pathology: An Update for 2018. Clinics in Laboratory Medicine, 38, 237-251. &lt;br&gt;https://doi.org/10.1016/j.cll.2018.02.003</mixed-citation></ref><ref id="hanspub.43083-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Qian, D., Chen, K., Deng, H., Rao, H., Huang, H., Liao, Y., et al. (2015) MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-Cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clinical Cancer Research, 21, 4881-4891. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-14-2947</mixed-citation></ref><ref id="hanspub.43083-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Qin, W., Xie, W., He, Q., Sun, T., Meng, C., Yang, K., et al. (2018) MicroRNA-152 Inhibits Ovarian Cancer Cell Proliferation and Migration and May Infer Improved Outcomes in Ovarian Cancer through Targeting FOXP1. Experimental and Therapeutic Medicine, 15, 1672-1679. &lt;br&gt;https://doi.org/10.3892/etm.2017.5529</mixed-citation></ref><ref id="hanspub.43083-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Grunewald, T. and Ledermann, J.A. (2017) Targeted Therapies for Ovarian Cancer. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology, 41, 139-152. &lt;br&gt;https://doi.org/10.1016/j.bpobgyn.2016.12.001</mixed-citation></ref><ref id="hanspub.43083-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Modugno, F. and Edwards, R.P. (2012) Ovarian Cancer: Prevention, Detection, and Treatment of the Disease and Its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report. International Journal of Gynecologic Cancer, 22, S45-S57. &lt;br&gt;https://doi.org/10.1097/IGC.0b013e31826bd1f2</mixed-citation></ref></ref-list></back></article>